par Lejeune, Bernard 
;Barlow, Patricia ;Puissant, Françoise ;Delvigne, Annick ;Vanrysselberge, M.;Leroy, Fernand
Référence Fertility and sterility, 54, 3, page (475-481)
Publication Publié, 1990
;Barlow, Patricia ;Puissant, Françoise ;Delvigne, Annick ;Vanrysselberge, M.;Leroy, Fernand Référence Fertility and sterility, 54, 3, page (475-481)
Publication Publié, 1990
Article révisé par les pairs
| Résumé : | A comparison has been established retrospectively between clomiphene citrate-human menopausal gonadotropin (CC-hMG) and buserelin acetate-hMG treatments in in vitro fertilization trials performed over a 3-year period. The analysis of 466 CC-hMG and 319 buserelin acetate-hMG trials shows that buserelin acetate-hMG stimulation generates a greater ovarian response resulting in higher numbers of oocytes being retrieved (6.2 + 3.8 versus 9.3 + 5.2) and fertilized (2.8 + 2.7 versus 4.3 + 3.8). More embryos are thus obtained, allowing a wider choice for intrauterine replacement and cryopreservation. Mean embryonic vitality scores do not differ (4.33 + 1.51 versus 4.44 + 1.54), implying that the embryonic quality remains similar in both treatments. A premature demise of the corpus luteum occurs in a large proportion of buserelin acetate-hMG cycles. However, when suppletive progesterone treatment is given, there is a trend toward a better implantation rate per embryo, and a significantly higher ongoing pregnancy rate is observed in relation to buserelin acetate-hMG treatment (20%) as compared with CC-hMG cycles (14%). |
